Elizabeth B. Andrews
Vice President, Pharmacoepidemiology and Risk Management, RTI-HS
Elizabeth Andrews, PhD, is the vice president of Pharmacoepidemiology and Risk Management at RTI Health Solutions. Dr. Andrews provides consultation for pharmaceutical companies and the U.S. Food and Drug Administration on therapeutic risk management and pharmacoepidemiology, and she directs research programs that evaluate drug safety and compliance with prescribing and treatment guidelines. She oversees the conduct of large, prospective patient registries, web-based surveys, and studies using large existing databases. Dr. Andrews has worked extensively in the areas of HIV and sexually transmitted diseases, birth defects and neonatal health, asthma and chronic obstructive pulmonary disease, and irritable bowel syndrome. She is a fellow and past president of the International Society for Pharmacoepidemiology, and coeditor of Pharmacovigilance. She is an adjunct associate professor of the University of North Carolina School of Public Health and School of Pharmacy, and a member of the Steering Committee for the Innovation in Medical Evidence Development and Surveillance (IMEDS) Program of the Reagan Udall Foundation for the FDA.
PhD, Epidemiology, University of North Carolina at Chapel Hill; MPH, Health Policy and Administration, University of North Carolina at Chapel Hill.
- Drug Safety
- Therapeutic Risk Management
- Therapeutic Outcomes and Safety
- December 11, 2014
New report explores pros and cons of working with real world medical data
- December 10, 2014
Pros and cons of using big data to monitor drug safety
- December 9, 2014
Report: The pros and cons of using big data to monitor drug safety
– News Release